Annual report
4323.TEDINET S100W4ZM
Period2024-04-01 → 2025-03-31
Filed2025-06-27
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 150
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥29.3bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥26.2bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥23.5bn | 2022-04-01 → 2023-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥21.4bn | 2021-04-01 → 2022-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥18.8bn | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥3.2bn | 2024-04-01 → 2025-03-31 | Cons. | Operating income |
| Operating income | ¥2.8bn | 2023-04-01 → 2024-03-31 | Cons. | Operating income |
| Ordinary income | ¥3.3bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥2.9bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥2.5bn | 2022-04-01 → 2023-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.1bn | 2021-04-01 → 2022-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.3bn | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥3.3bn | 2024-04-01 → 2025-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥2.9bn | 2023-04-01 → 2024-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.4bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.1bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.8bn | 2022-04-01 → 2023-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.3bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥579m | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥2.5bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss |
| Net income | ¥2.1bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss |
| Total assets | ¥22.9bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥20.0bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥17.4bn | at 2023-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥15.5bn | at 2022-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥12.9bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥8.1bn | at 2025-03-31 | Cons. | Liabilities |
| Total liabilities | ¥7.3bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥14.8bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥12.7bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥10.8bn | at 2023-03-31d | Cons. | Net assets |
| Net assets / equity | ¥9.2bn | at 2022-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥6.9bn | at 2021-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥7.1bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥8.0bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥6.7bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥7.5bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥6.8bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥6.5bn | at 2022-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥4.9bn | at 2021-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥1.8bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.9bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.1bn | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.2bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥2.1bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥2.0bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥761m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥542m | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥81m | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥87m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥599m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥424m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥281m | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥487m | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.2bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥99.24 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥85.08 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥72.25 | 2022-04-01 → 2023-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥56.16 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥26.99 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥26.98 | 2020-04-01 → 2021-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥596.97 | at 2025-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥516.08 | at 2024-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥439.03 | at 2023-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥373.43 | at 2022-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥316.49 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 64.4% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 63.2% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 61.8% | at 2023-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 58.9% | at 2022-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 53.0% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 17.8% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 17.8% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 17.8% | 2022-04-01 → 2023-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 16.7% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.9% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 1,613 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 1,847 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 1,687 | at 2023-03-31d | Cons. | Number of employees |
| Employees | 1,448 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 1,320 | at 2021-03-31d | Cons. | Number of employees |
| Revenue | ¥24.2bn | 2024-04-01 → 2025-03-31 | Standalone | Net sales |
| Revenue | ¥20.4bn | 2023-04-01 → 2024-03-31 | Standalone | Net sales |
| Revenue | ¥18.6bn | 2022-04-01 → 2023-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥17.1bn | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥15.2bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥3.0bn | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Operating income | ¥2.1bn | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Ordinary income | ¥3.4bn | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥2.2bn | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥2.1bn | 2022-04-01 → 2023-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.8bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.1bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥3.4bn | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥2.2bn | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Net income | ¥2.7bn | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥1.6bn | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥1.6bn | 2022-04-01 → 2023-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥1000m | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥401m | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥20.4bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥17.3bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥15.5bn | at 2023-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥14.0bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥11.8bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥6.8bn | at 2025-03-31 | Standalone | Liabilities |
| Total liabilities | ¥5.9bn | at 2024-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥13.7bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥11.4bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥10.2bn | at 2023-03-31d | Standalone | Net assets |
| Net assets / equity | ¥8.8bn | at 2022-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥6.9bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥5.1bn | at 2025-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥5.8bn | at 2024-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥109.22 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥65.82 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥66.47 | 2022-04-01 → 2023-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥42.19 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥18.71 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥18.7 | 2020-04-01 → 2021-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥27 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥45 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥32 | 2022-04-01 → 2023-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥40 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥28 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥552.55 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥466.42 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥415.93 | at 2023-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥358.96 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥320.15 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 66.9% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 65.9% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 65.8% | at 2023-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 63.0% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 58.5% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 21.4% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 14.9% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 17.2% | 2022-04-01 → 2023-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 12.7% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.0% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 24,836,920 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 12,418,460 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 12,418,460 | at 2023-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 6,209,230 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 5,612,230 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 1,151 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 1,009 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 926 | at 2023-03-31d | Standalone | Number of employees |
| Employees | 871 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 827 | at 2021-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 69
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2025-03-31 | −¥114m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2025-03-31 | −¥114m |
| Reconciling Itemsreconciling | segment assets | at 2025-03-31 | ¥3.3bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | −¥1.8bn |
| Global Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥93m |
| Global Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥76m |
| Global Businessreportable segment | employees | at 2025-03-31 | 275 pure |
| Global Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥2.8bn |
| Global Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥2.8bn |
| Global Businessreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥79m |
| Global Businessreportable segment | segment assets | at 2025-03-31 | ¥2.4bn |
| Global Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | −¥62m |
| Medical Big Data Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥49m |
| Medical Big Data Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥33m |
| Medical Big Data Businessreportable segment | employees | at 2025-03-31 | 176 pure |
| Medical Big Data Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥3.2bn |
| Medical Big Data Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥3.2bn |
| Medical Big Data Businessreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥556,000 |
| Medical Big Data Businessreportable segment | segment assets | at 2025-03-31 | ¥2.8bn |
| Medical Big Data Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥662m |
| Package Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥53m |
| Package Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥37m |
| Package Businessreportable segment | employees | at 2025-03-31 | 267 pure |
| Package Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥5.9bn |
| Package Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥5.9bn |
| Package Businessreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥4m |
| Package Businessreportable segment | segment assets | at 2025-03-31 | ¥4.7bn |
| Package Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥1.6bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2024-04-01 → 2025-03-31 | ¥329m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2024-04-01 → 2025-03-31 | ¥237m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2025-03-31 | ¥29.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2025-03-31 | ¥29.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥114m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2025-03-31 | ¥19.6bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2025-03-31 | ¥5.0bn |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2024-03-31 | −¥206m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2024-03-31 | −¥206m |
| Reconciling Itemsreconciling | segment assets | at 2024-03-31 | ¥2.2bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥1.9bn |
| Global Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥44m |
| Global Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥56m |
| Global Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥3.4bn |
| Global Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥3.4bn |
| Global Businessreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥70m |
| Global Businessreportable segment | segment assets | at 2024-03-31 | ¥2.4bn |
| Global Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥402m |
| Medical Big Data Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥60m |
| Medical Big Data Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥26m |
| Medical Big Data Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥2.6bn |
| Medical Big Data Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥2.6bn |
| Medical Big Data Businessreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥3m |
| Medical Big Data Businessreportable segment | segment assets | at 2024-03-31 | ¥2.6bn |
| Medical Big Data Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥686m |
| Package Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥117m |
| Package Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥33m |
| Package Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥4.9bn |
| Package Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥4.9bn |
| Package Businessreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥6m |
| Package Businessreportable segment | segment assets | at 2024-03-31 | ¥4.0bn |
| Package Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥1.4bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2023-04-01 → 2024-03-31 | ¥526m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2023-04-01 → 2024-03-31 | ¥196m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2024-03-31 | ¥26.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2024-03-31 | ¥26.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥206m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2024-03-31 | ¥17.8bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2024-03-31 | ¥4.7bn |
| Medical Big Data Businessreportable segment | employees | at 2025-03-31 | 107 pure |
| Package Businessreportable segment | employees | at 2025-03-31 | 261 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,567
| Item | Context | Value | Unit |
|---|---|---|---|
| Type of current period | FilingDateInstant | FY | |
| Current fiscal year end date | FilingDateInstant | 2025-03-31 | |
| Previous fiscal year start date | FilingDateInstant | 2023-04-01 | |
| Comparative period end date | FilingDateInstant | 2024-03-31 | |
| Previous fiscal year end date | FilingDateInstant | 2024-03-31 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of group (text) | FilingDateInstant | Text · Plus | |
| Business results of reporting company (text) | FilingDateInstant | Text · Plus | |
| Company history (text) | FilingDateInstant | Text · Plus | |
| Description of business (text) | FilingDateInstant | Text · Plus | |
| Overview of affiliated entities (text) | FilingDateInstant | Text · Plus | |
| Information about employees (text) | FilingDateInstant | Text · Plus | |
| Business policy business environment issues to address etc (text) | FilingDateInstant | Text · Plus | |
| Disclosure of sustainability related financial information (text) | FilingDateInstant | Text · Plus | |
| Governance (text) | FilingDateInstant | Text · Plus | |
| Strategy (text) | FilingDateInstant | Text · Plus | |
| Policy on development of human resources and internal environment strategy (text) | FilingDateInstant | Text · Plus | |
| Risk management (text) | FilingDateInstant | Text · Plus | |
| Reference to other information risk management | FilingDateInstant | Original text (Japanese)「３ 事業等のリスク」 | |
| Metrics and targets (text) | FilingDateInstant | Text · Plus | |
| Description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics metrics and targets (text) | FilingDateInstant | Text · Plus | |
| Metrics description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row1Member | Original text (Japanese)管理職に占める女性労働者の割合 | |
| Target period description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row1Member | Original text (Japanese)2028年3月まで | |
| Metrics unit description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row1Member | % | |
| Metrics description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row2Member | Original text (Japanese)男性労働者の育児休業取得率 | |
| Target period description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row2Member | Original text (Japanese)2028年3月まで | |
| Metrics unit description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row2Member | % | |
| Metrics description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row3Member | Original text (Japanese)労働者の男女の賃金の差異 | |
| Target period description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row3Member | Original text (Japanese)2028年3月まで | |
| Metrics unit description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row3Member | % | |
| Reference to other information metrics and targets | FilingDateInstant | Text · Plus | |
| Business risks (text) | FilingDateInstant | Text · Plus | |
| Management analysis of financial position operating results and cash flows (text) | FilingDateInstant | Text · Plus | |
| Critical contracts (text) | FilingDateInstant | Text · Plus | |
| Research and development activities (text) | FilingDateInstant | Text · Plus | |
| Overview of capital expenditures etc (text) | FilingDateInstant | Text · Plus | |
| Major facilities (text) | FilingDateInstant | Text · Plus | |
| Planned additions retirements etc of facilities (text) | FilingDateInstant | Text · Plus | |
| Total number of shares (text) | FilingDateInstant | Text · Plus | |
| Issued shares total number of shares etc (text) | FilingDateInstant | Text · Plus | |
| Class issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)普通株式 | |
| Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registered | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)東京証券取引所プライム市場 | |
| Description issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)権利内容に何ら限定のない当社における標準となる株式であり、単元株式数は100株であります。 | |
| Details of employee share option program (text) | FilingDateInstant | Text · Plus | |
| Description of rights plan (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |